Patient P-02185
Therapy response
Improving
Tolerance
Unstable
GI state
Stable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
73%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S14
- Day 68 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 77 GI-04 recommended — GI Support Protocol GI-04
- Day 78 Patient accepted — Started GI-04 in the companion
- Day 78 ME-01 recommended — Monitoring Escalation ME-01
- Day 79 Patient accepted — Started ME-01 in the companion
- Day 82 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
- Day 86 GI symptom burden −33% vs expected — GI Support Protocol GI-04
- Day 92 Tolerance state changed — Unstable → Improving
What changed?
Trajectory began diverging from predicted response on Day 68.
Primary contributors, last 14 days
- Inflammatory activity+13
- Toxicity+9
- Nutritional resilience-7
- GI instability+2
- Treatment adherence-2
What helped?
- GI Support Protocol GI-04Day 77Result: symptom burden −33%
- Monitoring Escalation ME-01Day 78Result: deterioration detected before clinical escalation
LIFE OS recommendation
Supportive Compound SC-12
63%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 69% showed improvement
- median effect visible after 6 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 29/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 65
- WearableHRV 25 ms, trending down
- Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 52 and rising
- Drug metabolism and exposure ↑20
- BloodToxicity index 59
- Autonomic recovery ↓20
- Wearable1,471 steps/day
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 3 · butyrate capacity 29/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisHigh
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 27 ms
- Sleep
- 6.5 h
- Steps
- 1,256
- Resting HR
- 73 bpm
Daily log: GI score 52, nutritional resilience 38, adherence 53.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02093 | 20% | S05 | AD-05 | no change | 40 |
| P-02483 | 23% | S06 | BR-03 | no change | 64 |
| P-02564 | 21% | S15 | BR-03 | improved | 32 |
| P-02087 | 20% | S01 | BR-03 | no change | 40 |
| P-02009 | 36% | S08 | CR-01 | improved | 64 |
| P-02054 | 33% | S01 | CR-01 | improved | 57 |
| P-02151 | 33% | S04 | CR-01 | improved | 49 |
| P-02025 | 31% | S15 | CR-01 | improved | 61 |
| P-02154 | 30% | S16 | CR-01 | improved | 57 |
| P-02233 | 29% | S16 | CR-01 | improved | 66 |
| P-02274 | 22% | S15 | DT-01 | improved | 50 |
| P-02339 | 22% | S03 | DT-01 | improved | 50 |